| 词条 | Onchocerciasis |
| 释义 |
| name = Onchocerciasis | synonyms = River blindness, Robles disease | image = Onchocerca volvulus emerging from a black fly.jpg | caption = An adult black fly with the parasite Onchocerca volvulus coming out of the insect's antenna, magnified 100x | pronounce = {{IPAc-en|ˌ|ɒ|ŋ|k|oʊ|s|ɜːr|ˈ|s|aɪ|ə|s|ᵻ|s|,_|-|ˈ|k|aɪ|-}} | field = Infectious disease | symptoms = Itching, bumps under the skin, blindness[1] | complications = | onset = | duration = | causes = Onchocerca volvulus spread by a black fly[1] | risks = | diagnosis = | differential = | prevention = Avoiding bites (insect repellent, proper clothing)[3] | treatment = | medication = Ivermectin, doxycycline[4][5] | prognosis = | frequency = 15.5 million (2015)[6] | deaths = }}Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm Onchocerca volvulus.[1] Symptoms include severe itching, bumps under the skin, and blindness.[1] It is the second-most common cause of blindness due to infection, after trachoma.[9] The parasite worm is spread by the bites of a black fly of the Simulium type.[1] Usually, many bites are required before infection occurs.[2] These flies live near rivers, hence the common name of the disease.[3] Once inside a person, the worms create larvae that make their way out to the skin,[1] where they can infect the next black fly that bites the person.[1] There are a number of ways to make the diagnosis, including: placing a biopsy of the skin in normal saline and watching for the larva to come out, looking in the eye for larvae, and looking within the bumps under the skin for adult worms.[4] A vaccine against the disease does not exist.[1] Prevention is by avoiding being bitten by flies.[5] This may include the use of insect repellent and proper clothing.[5] Other efforts include those to decrease the fly population by spraying insecticides.[1] Efforts to eradicate the disease by treating entire groups of people twice a year are ongoing in a number of areas of the world.[1] Treatment of those infected is with the medication ivermectin every six to twelve months.[1][4] This treatment kills the larvae but not the adult worms.[6] The antibiotic doxycycline weakens the worms by killing an associated bacterium called Wolbachia, and is recommended by some as well.[6] The lumps under the skin may also be removed by surgery.[7] About 15.5 million people are infected with river blindness.[8] Approximately 0.8 million have some amount of loss of vision from the infection.[2][6] Most infections occur in sub-Saharan Africa, although cases have also been reported in Yemen and isolated areas of Central and South America.[1] In 1915, the physician Rodolfo Robles first linked the worm to eye disease.[9] It is listed by the World Health Organization (WHO) as a neglected tropical disease.[10] Signs and symptomsAdult worms remain in subcutaneous nodules, limiting access to the host's immune system.[11] Microfilariae, in contrast, are able to induce intense inflammatory responses, especially upon their death. Wolbachia species have been found to be endosymbionts of O. volvulus adults and microfilariae, and are thought to be the driving force behind most of O. volvulus morbidity. Dying microfilariae have been recently discovered to release Wolbachia surface protein that activates TLR2 and TLR4, triggering innate immune responses and producing the inflammation and its associated morbidity.[12] The severity of illness is directly proportional to the number of infected microfilariae and the power of the resultant inflammatory response.[13] Skin involvement typically consists of intense itching, swelling, and inflammation.[14] A grading system has been developed to categorize the degree of skin involvement:[15][16][17]
Ocular involvement provides the common name associated with onchocerciasis, river blindness, and may involve any part of the eye from conjunctiva and cornea to uvea and posterior segment, including the retina and optic nerve.[14] The microfilariae migrate to the surface of the cornea. Punctate keratitis occurs in the infected area. This clears up as the inflammation subsides. However, if the infection is chronic, sclerosing keratitis can occur, making the affected area become opaque. Over time, the entire cornea may become opaque, thus leading to blindness. Some evidence suggests the effect on the cornea is caused by an immune response to bacteria present in the worms.[13] The infected person's skin is itchy, with severe rashes permanently damaging patches of skin. Mazzotti reaction{{main|Mazzotti reaction}}The Mazzotti reaction, first described in 1948, is a symptom complex seen in patients after undergoing treatment of onchocerciasis with the medication diethylcarbamazine (DEC). Mazzotti reactions can be life-threatening, and are characterized by fever, urticaria, swollen and tender lymph nodes, tachycardia, hypotension, arthralgias, oedema, and abdominal pain that occur within seven days of treatment of microfilariasis. The phenomenon is so common when DEC is used that this drug is the basis of a skin patch test used to confirm that diagnosis. The drug patch is placed on the skin, and if the patient is infected with O. volvulus microfilaria, localized pruritus and urticaria are seen at the application site.[18] Nodding disease{{Main|Nodding disease}}This is an unusual form of epidemic epilepsy associated with onchocerciasis although definitive link has not been established.[19] This syndrome was first described in Tanzania by Louise Jilek-Aall, a Norwegian psychiatric doctor in Tanzanian practice, during the 1960s. It occurs most commonly in Uganda and South Sudan. It manifests itself in previously healthy 5–15-year-old children, is often triggered by eating or low temperatures and is accompanied by cognitive impairment. Seizures occur frequently and may be difficult to control. The electroencephalogram is abnormal but cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) are normal or show non-specific changes. If there are abnormalities on the MRI they are usually present in the hippocampus. Polymerase chain reaction testing of the CSF does not show the presence of the parasite. ClassificationOnchocerciasis causes different kinds of skin changes, which vary in different geographic regions; it may be divided into the following phases or types:[20]{{rp|440–441}}{{Verify source|date=May 2010}}
An acute phase, it is characterized by swelling of the face, with erythema and itching.[20]{{rp|440}} This skin change, erisípela de la costa, of acute onchocerciasis is most commonly seen among victims in Central and South America.[21]
This cutaneous condition is characterized by inflammation accompanied by hyperpigmentation.[20]{{rp|440}}
A cutaneous condition, it is a localized type of onchocerciasis.[20]{{rp|440}} Additionally, the various skin changes associated with onchocerciasis may be described as follows:[20]{{rp|440}}
The spotted depigmentation of the skin that may occur with onchocerciasis[20]{{rp|440}}
The thickening of human skin that may be associated with onchocerciasis[20]{{rp|440}}
The thickened, wrinkled skin changes that may result with onchocerciasis[20]{{rp|441}} CauseThe cause is Onchocerca volvulus. Life cycleThe life of the parasite can be traced through the black fly and the human hosts in the following steps:[22][23]
PreventionVarious control programs aim to stop onchocerciasis from being a public health problem. The first was the Onchocerciasis Control Programme (OCP), which was launched in 1974, and at its peak, covered 30 million people in 11 countries. Through the use of larvicide spraying of fast-flowing rivers to control black fly populations, and from 1988 onwards, the use of ivermectin to treat infected people, the OCP eliminated onchocerciasis as a public health problem. The OCP, a joint effort of the World Health Organisation, the World Bank, the United Nations Development Programme, and the UN Food and Agriculture Organization, was considered to be a success, and came to an end in 2002. Continued monitoring ensures onchocerciasis cannot reinvade the area of the OCP.[24] In 1995, the African Programme for Onchocerciasis Control began covering another 19 countries, mainly relying upon the use of ivermectin. Its goal is to set up a community-directed supply of ivermectin for those who are infected. In these ways, transmission has declined.[25] In 2015, WHO was facilitating launch of an elimination program in Yemen. In 1992, the Onchocerciasis Elimination Programme for the Americas, which also relies on ivermectin, was launched.[26] On July 29, 2013, the Pan American Health Organization (PAHO) announced that after 16 years of efforts, Colombia had become the first country in the world to eliminate onchocerciasis.[27] In September 2015, the Onchocerciasis Elimination Program for the Americas announced that onchocerciasis only remained in a remote region on the border of Brazil and Venezuela.[28][29] The area is home to the Yanomami indigenous people. The first countries to receive verification of elimination were Colombia in 2013, Ecuador in 2014, and Mexico in 2015.[30] Guatemala has submitted a request for verification. The key factor in elimination is mass administration of the antiparasitic drug ivermectin. The initial projection was that the disease would be eliminated from remaining foci in the Americas by 2012.[31] No vaccine to prevent onchocerciasis infection in humans is available. A vaccine to prevent onchocerciasis infection for cattle is in phase three trials. Cattle injected with a modified and weakened form of O. ochengi larvae have developed very high levels of protection against infection. The findings suggest that it could be possible to develop a vaccine that protects people against river blindness using a similar approach. Unfortunately, a vaccine to protect humans is still many years off.[32][33] TreatmentIn mass drug administration (MDA) programmes, the treatment for onchocerciasis is ivermectin (trade name: Mectizan); infected people can be treated with two doses of ivermectin, six months apart, repeated every three years. The drug paralyses and kills the microfilariae causing fever, itching, and possibly oedema, arthritis and lymphadenopathy. Intense skin itching is eventually relieved, and the progression towards blindness is halted. In addition, while the drug does not kill the adult worms, it does prevent them for a limited time from producing additional offspring. The drug therefore prevents both morbidity and transmission for up to several months. Ivermectin treatment is particularly effective because it only needs to be taken once or twice a year, needs no refrigeration, and has a wide margin of safety, with the result that it has been widely given by minimally trained community health workers.[34] AntibioticsFor the treatment of individuals, doxycycline is used to kill the Wolbachia bacteria that live in adult worms. This adjunct therapy has been shown to significantly lower microfilarial loads in the host, and may kill the adult worms, due to the symbiotic relationship between Wolbachia and the worm.[35][36][37] In four separate trials over ten years with various dosing regimens of doxycycline for individualized treatment, doxycycline was found to be effective in sterilizing the female worms and reducing their numbers over a period of four to six weeks. Research on other antibiotics, such as rifampicin, has shown it to be effective in animal models at reducing Wolbachia both as an alternative and as an adjunct to doxycycline.[38] However, doxycycline treatment requires daily dosing for at least four to six weeks, making it more difficult to administer in the affected areas.[34] IvermectinIvermectin kills the parasite by interfering with the nervous system and muscle function, in particular, by enhancing inhibitory neurotransmission. The drug binds to and activates glutamate-gated chloride channels.[34] These channels, present in neurons and myocytes, are not invertebrate-specific, but are protected in vertebrates from the action of ivermectin by the blood–brain barrier.[34] Ivermectin is thought to irreversibly activate these channel receptors in the worm, eventually causing an inhibitory postsynaptic potential. The chance of a future action potential occurring in synapses between neurons decreases and the nematodes experience flaccid paralysis followed by death.[39][40][41]Ivermectin is directly effective against the larval stage microfilariae of O. volvulus; they are paralyzed and can be killed by eosinophils and macrophages. It does not kill adult females (macrofilariae), but does cause them to cease releasing microfilariae, perhaps by paralyzing the reproductive tract.[34] Ivermectin is very effective in reducing microfilarial load and reducing number of punctate opacities in individuals with onchocerciasis.[42] MoxidectinMoxidectin was approved for onchocerciasis in 2018 for people over the age of 11 in the United States.[77] The safety of multiple doses is unclear.[43]EpidemiologyAbout 37 million people are infected with this parasite;[44] about 300,000 of those had been permanently blinded.[45] As of 2008, about 99% of onchocerciasis cases occurred in Africa.[46] Onchocerciasis is currently endemic in 31 African countries, Yemen, and isolated regions of South America.[47] Over 85 million people live in endemic areas, and half of these reside in Nigeria. Another 120 million people are at risk for contracting the disease. Due to the vector’s breeding habitat, the disease is more severe along the major rivers in the northern and central areas of the continent, and severity declines in villages farther from rivers.[48] Onchocerciasis was eliminated in the northern focus in Chiapas, Mexico,[49] and the focus in Oaxaca, Mexico, where Onchocerca volvulus existed, was determined, after several years of treatment with ivermectin, as free of the transmission of the parasite.[50] According to a 2002 WHO report, onchocerciasis has not caused a single death, but its global burden is 987,000 disability adjusted life years (DALYs). The severe pruritus alone accounts for 60% of the DALYs. Infection reduces the host’s immunity and resistance to other diseases, which results in an estimated reduction in life expectancy of 13 years.[47] HistoryOnchocerca originated in Africa and was exported to the Americas by the slave trade, as part of the Columbian exchange that introduced other old world diseases such as yellow fever into the New World. Findings of a phylogenetic study in the mid-90s are consistent with an introduction to the New World in this manner. DNA sequences of savannah and rainforest strains in Africa differ, while American strains are identical to savannah strains in western Africa.[51] The microfilarial parasite that causes the disease was first identified in 1874 by an Irish naval surgeon, John O’Neill, who was seeking to identify the cause of a common skin disease along the west coast of Africa, known as “craw-craw”.[52] Rudolf Leuckart, a German zoologist, later examined specimens of the same filarial worm sent from Africa by a German missionary doctor in 1890 and named the organism Filaria volvulus.[53] Rodolfo Robles and Rafael Pacheco in Guatemala first mentioned the ocular form of the disease in the Americas about 1915. They described a tropical worm infection with adult Onchocerca that included inflammation of the skin, especially the face (‘erisipela de la costa’), and eyes.[54] The disease, commonly called the “filarial blinding disease”, and later referred to as “Robles disease”, was common among coffee plantation workers. Manifestations included subcutaneous nodules, anterior eye lesions, and dermatitis. Robles sent specimens to Émile Brumpt, a French parasitologist, who named it O. caecutiens in 1919, indicating the parasite caused blindness (Latin “caecus” meaning blind).[55] The disease was also reported as being common in Mexico.[56] By the early 1920s, it was generally agreed that the filaria in Africa and Central America were morphologically indistinguishable and the same as that described by O’Neill 50 years earlier. Robles hypothesized that the vector of the disease was the day-biting black fly, Simulium. Scottish physician Donald Blacklock of the Liverpool School of Tropical Medicine confirmed this mode of transmission in studies in Sierra Leone. Blacklock’s experiments included the re-infection of Simulium flies exposed to portions of the skin of infected subjects on which nodules were present, which led to elucidation of the life cycle of the Onchocerca parasite.[57] Blacklock and others could find no evidence of eye disease in Africa. Jean Hissette, a Belgian ophthalmologist, discovered in 1930 that the organism was the cause of a “river blindness” in the Belgian Congo.[58] Some of the patients reported seeing tangled threads or worms in their vision, which were microfilariae moving freely in the aqueous humor of the anterior chamber of the eye.[59] Blacklock and Strong had thought the African worm did not affect the eyes, but Hissette reported that 50% of patients with onchocerciasis near the Sankuru river in the Belgian Congo had eye disease and 20% were blind. Hisette Isolated the microfilariae from an enucleated eye and described the typical chorioretinal scarring, later called the “Hissette-Ridley fundus” after another ophthalmologist, Harold Ridley, who also made extensive observations on onchocerciasis patients in north west Ghana, publishing his findings in 1945.[60] Ridley first postulated that the disease was brought by the slave trade. The international scientific community was initially skeptical of Hisette’s findings, but they were confirmed by the Harvard African Expedition of 1934, led by Richard P. Strong, an American physician of tropical medicine.[61] Society and cultureSince 1987, ivermectin has been provided free of charge for use in humans by Merck through the Mectizan donation program (MDP). The MDP works together with ministries of health and nongovernmental development organisations, such as the World Health Organization, to provide free ivermectin to those who need it in endemic areas.[62] In 2015 William C. Campbell and Satoshi Ōmura were co-awarded half of that year's Nobel Prize in Physiology or Medicine for the discovery of the avermectin family of compounds, the forerunner of ivermectin. The latter has come to decrease the occurrence of lymphatic filariasis and onchoceriasis.[63] Uganda's government, working with the Carter Center river blindness program since 1996, switched strategies for distribution of Mectizan. The male-dominated volunteer distribution system had failed to take advantage of traditional kinship structures and roles. The program switched in 2014 from village health teams to community distributors, primarily selecting women with the goal of assuring that everyone in the circle of their family and friends received river blindness information and Mectizan.[64] ResearchAnimal models for the disease are somewhat limited, as the parasite only lives in primates, but there are close parallels. Litomosoides sigmodontis , which will naturally infect cotton rats, has been found to fully develop in BALB/c mice. Onchocerca ochengi, the closest relative of O. volvulus, lives in intradermal cavities in cattle, and is also spread by black flies. Both systems are useful, but not exact, animal models.[65] A study of 2501 people in Ghana showed the prevalence rate doubled between 2000 and 2005 despite treatment, suggesting the parasite is developing resistance to the drug.[38][66][67] A clinical trial of another antiparasitic agent, moxidectin (manufactured by Wyeth), began on July 1, 2009 (NCT00790998).[68] A Cochrane review compared outcomes of people treated with ivermectin alone versus doxycycline plus ivermectin. While there were no differences in most vision-related outcomes between the two treatments, there was low quality evidence suggesting treatment with doxycycline plus ivermectine showed improvement in iridocyclitis and punctate keratitis, over those treated with ivermectine alone.[69] See also{{portal|Medicine}}
References1. ^1 2 3 4 5 6 7 8 9 10 11 {{cite web|title=Onchocerciasis Fact sheet N°374|url=http://www.who.int/mediacentre/factsheets/fs374/en/|work=World Health Organization|access-date=20 March 2014|date=March 2014|deadurl=no|archiveurl=https://web.archive.org/web/20140316195959/http://www.who.int/mediacentre/factsheets/fs374/en/|archivedate=16 March 2014|df=}} 2. ^1 {{cite web|title=Parasites – Onchocerciasis (also known as River Blindness) Epidemiology & Risk Factors|url=https://www.cdc.gov/parasites/onchocerciasis/epi.html|work=CDC|access-date=20 March 2014|date=21 May 2013|deadurl=no|archiveurl=https://web.archive.org/web/20140419014141/http://www.cdc.gov/parasites/onchocerciasis/epi.html|archivedate=19 April 2014|df=}} 3. ^1 {{cite web|title=Onchocerciasis (also known as River Blindness)|work=Parasites|url=https://www.cdc.gov/parasites/onchocerciasis/|publisher=CDC|access-date=20 March 2014|date=21 May 2013|deadurl=no|archiveurl=https://web.archive.org/web/20140226071647/http://www.cdc.gov/parasites/onchocerciasis/|archivedate=26 February 2014|df=}} 4. ^{{cite web |title=Onchocerciasis (also known as River Blindness) Diagnosis |publisher=CDC |url=https://www.cdc.gov/parasites/onchocerciasis/diagnosis.html |work=Parasites |access-date=20 March 2014 |date=21 May 2013 |deadurl=no |archiveurl=https://web.archive.org/web/20140419025103/http://www.cdc.gov/parasites/onchocerciasis/diagnosis.html |archivedate=19 April 2014 |df= }} 5. ^1 2 {{cite web |title=Onchocerciasis (also known as River Blindness) Prevention & Control |url=https://www.cdc.gov/parasites/onchocerciasis/prevent.html |work=Parasites |publisher=CDC |access-date=20 March 2014 |date=May 21, 2013 |deadurl=no |archiveurl=https://web.archive.org/web/20140419012306/http://www.cdc.gov/parasites/onchocerciasis/prevent.html |archivedate=19 April 2014 |df= }} 6. ^1 2 3 {{cite book|last=Brunette|first=Gary W.|title=CDC Health Information for International Travel 2012 : The Yellow Book|year=2011|publisher=Oxford University Press|isbn=9780199830367|page=258|url=https://books.google.com/books?id=5vCQpr1WTS8C&pg=PA258|deadurl=no|archiveurl=https://web.archive.org/web/20170908221523/https://books.google.com/books?id=5vCQpr1WTS8C&pg=PA258|archivedate=2017-09-08|df=}} 7. ^1 2 {{cite book |last=Murray |first=Patrick |title=Medical microbiology |year=2013 |publisher=Elsevier Saunders |location=Philadelphia |isbn=9780323086929 |page=792 |url=https://books.google.com/books?id=RBEVsFmR2yQC&pg=PA792 |edition=7th |deadurl=no |archiveurl=https://web.archive.org/web/20170908221523/https://books.google.com/books?id=RBEVsFmR2yQC&pg=PA792 |archivedate=2017-09-08 |df= }} 8. ^1 {{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}} 9. ^{{cite book |editor1=Eldridge, Bruce F. |editor2=Edman, John D. |editor3=Edman, J. |title=Medical entomology |year=2004 |publisher=Kluwer Academic |location=Dordrecht |isbn=9781402017940 |page=301 |chapter-url=https://books.google.com/books?id=C7OxOqTKYS8C&pg=PA301 |edition=Revised |author1=Lok, James B. |author2=Walker, Edward D. |author3=Scoles, Glen A. |chapter=9. Filariasis |deadurl=no |archiveurl=https://web.archive.org/web/20170908221523/https://books.google.com/books?id=C7OxOqTKYS8C&pg=PA301 |archivedate=2017-09-08 |df= }} 10. ^{{cite journal |vauthors=Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA |title=Oral drug therapy for multiple neglected tropical diseases: a systematic review |journal=JAMA |volume=298 |issue=16 |pages=1911–24 |date=October 2007 |doi=10.1001/jama.298.16.1911 |pmid=17954542 }} 11. ^{{cite journal |last1=Stewart |last2=Boussinesq |last3=Coulson |last4=Elson |last5=Nutman |last6=Bradley |title=Onchocerciasis modulates the immune response to mycobacterial antigens |journal=Clinical and Experimental Immunology |date=September 1999 |volume=117 |issue=3 |pages=517–523 |doi=10.1046/j.1365-2249.1999.01015.x}} 12. ^{{cite journal |journal=BMC Evol Biol |date=2010-02-17|pages=10:48 |title=Accelerated microevolution in an outer membrane protein (OMP) of the intracellular bacteria Wolbachia |vauthors=Baldo L, Desjardins CA, Russell JA, Stahlhut JK, Werren JH |pmid=20163713 |pmc=2843615 |doi=10.1186/1471-2148-10-48 |volume=10}} 13. ^1 {{cite journal |journal=Clinical Microbiology Reviews |date=2011-07-24|pages=459–468 |title=Onchocerciasis: the Role of Wolbachia Bacterial Endosymbionts in Parasite Biology, Disease Pathogenesis, and Treatment |author1=Francesca Tamarozzi |author2=Alice Halliday |author3=Katrin Gentil |author4=Achim Hoerauf |author5=Eric Pearlman |author6=Mark J. Taylor |pmid=21734243 |pmc=3131055 |doi=10.1128/CMR.00057-10 |volume=24|issue=3}} 14. ^1 {{cite journal |author=Wani, MG |date=February 2008 |url=http://www.southernsudanmedicaljournal.com/archive/2008-02/oncocerciasis.html |title=Onchocerciasis |journal=Southern Sudan Medical Journal |deadurl=no |archiveurl=https://web.archive.org/web/20110115135137/http://www.southernsudanmedicaljournal.com/archive/2008-02/oncocerciasis.html |archivedate=2011-01-15 |df= }} 15. ^{{cite journal |title=Immune responses directed against microfilariae correlate with severity of clinical onchodermatitis and treatment history |vauthors=Ali MM, Baraka OZ, AbdelRahman SI, Sulaiman SM, Williams JF, Homeida MM, Mackenzie CD |journal=Journal of Infectious Diseases |volume=187 |issue=4 |date=15 February 2003 |pages=714–7 |pmid=12599094|jstor=30085595 |doi=10.1086/367709 }} 16. ^{{cite journal|journal=Br J Dermatol |date=September 1993 |volume=129 |issue=3|pages=260–9|title=A clinical classification and grading system of the cutaneous changes in onchocerciasis |vauthors=Murdoch ME, Hay RJ, Mackenzie CD, Williams JF, Ghalib HW, Cousens S, Abiose A, Jones BR |doi=10.1111/j.1365-2133.1993.tb11844.x |pmid=8286222}} 17. ^{{Cite web|url=https://www.academia.edu/15144397|title=A clinical classification and grading system of the cutaneous changes in onchocerciasis|last=Abiose|first=Adenike|date=March 1993|website=academia.edu|archive-url=|archive-date=|dead-url=|access-date=}} 18. ^{{cite web |url=http://microblog.me.uk/420 |title=Archived copy |accessdate=2011-01-25 |deadurl=no |archiveurl=https://web.archive.org/web/20101220070921/http://microblog.me.uk/420 |archivedate=2010-12-20 |df= }} 19. ^{{cite journal |vauthors=Dowell SF, Sejvar JJ, Riek L, Vandemaele KA, Lamunu M, Kuesel AC, Schmutzhard E, Matuja W, Bunga S, Foltz J, Nutman TB, Winkler AS, Mbonye AK |year=2013 |title=Nodding syndrome |journal=Emerg Infect Dis |volume=19 |issue=9 |pages=1374–3 |doi=10.3201/eid1909.130401 |pmid=23965548 |pmc=3810928}} 20. ^1 2 3 4 5 6 7 {{cite book |author1=James, William D. |author2=Berger, Timothy G. |author3=Elston, Dirk M |author4=Odom, Richard B. |title=Andrews' Diseases of the Skin: clinical dermatology |publisher=Saunders Elsevier |location= |year=2006 |edition=10th |isbn=978-0-7216-2921-6 |oclc=62736861 }} 21. ^{{cite web |url=http://emedicine.medscape.com/article/1109642-overview |title=Filariasis |author=Marty AM |accessdate=2009-10-22 |work=eMedicine |deadurl=no |archiveurl=https://web.archive.org/web/20090927035901/http://emedicine.medscape.com/article/1109642-overview |archivedate=2009-09-27 |df= }} 22. ^{{Cite web|url=https://www.cdc.gov/parasites/onchocerciasis/biology.html|title=Parasites - Onchocerciasis (also known as River Blindness)|last=|first=|date=|website=Centers for Disease Control and Prevention|archive-url=|archive-date=|dead-url=|access-date=}} 23. ^{{Cite web|url=https://web.stanford.edu/class/humbio103/ParaSites2006/Onchocerciasis/life%20cycle.html|title=Life Cycle|last=|first=|date=|website=Stanford University|archive-url=|archive-date=|dead-url=|access-date=}} 24. ^{{cite web |url=http://www.who.int/blindness/partnerships/onchocerciasis_OCP/en/index.html |title=Onchocerciasis Control Programme (OCP) |publisher=World Health Organization |work=Programmes and Projects |accessdate=2010-06-15 |deadurl=no |archiveurl=https://web.archive.org/web/20091124092752/http://www.who.int/blindness/partnerships/onchocerciasis_OCP/en/index.html |archivedate=2009-11-24 |df= }} 25. ^{{cite web |url=http://www.who.int/blindness/partnerships/APOC/en/index.html |title=African Programme for Onchocerciasis Control (APOC) |publisher=World Health Organization |work=Programmes and Projects |accessdate=2010-06-15 |deadurl=no |archiveurl=https://web.archive.org/web/20090828025547/http://www.who.int/blindness/partnerships/APOC/en/index.html |archivedate=2009-08-28 |df= }} 26. ^{{cite web |url=http://www.who.int/blindness/partnerships/onchocerciasis_oepa/en/index.html |title=Onchocerciasis Elimination Program for the Americas (OEPA) |publisher=World Health Organization |work=Programmes and Projects |accessdate=2010-06-15 |deadurl=no |archiveurl=https://web.archive.org/web/20110416031503/http://www.who.int/blindness/partnerships/onchocerciasis_oepa/en/index.html |archivedate=2011-04-16 |df= }} 27. ^{{cite news |title=NEWS SCAN: Columbia ousts river blindness; Vaccine-derived polio in India; Danish Salmonella trends |url=http://www.cidrap.umn.edu/news-perspective/2013/07/news-scan-jul-30-2013 |newspaper=CIDRAP News |date=July 30, 2013 |deadurl=no |archiveurl=https://web.archive.org/web/20131711191700/http://www.cidrap.umn.edu/news-perspective/2013/07/news-scan-jul-30-2013 |archivedate=September 8, 2017 |df= }} 28. ^{{cite web|title=Brazil and Venezuela border is the last place in the Americas with river blindness|url=http://outbreaknewstoday.com/brazil-and-venezuela-border-is-the-last-place-in-the-americas-with-river-blindness-13946/|publisher=Outbreak News Today|accessdate=3 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151001231057/http://outbreaknewstoday.com/brazil-and-venezuela-border-is-the-last-place-in-the-americas-with-river-blindness-13946/|archivedate=1 October 2015|df=}} 29. ^{{cite web|title=Onchocerciasis Elimination Program for the Americas (OEPA)|url=http://www.who.int/blindness/partnerships/onchocerciasis_oepa/en/|publisher=World Health Organization|accessdate=3 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20150920015329/http://www.who.int/blindness/partnerships/onchocerciasis_oepa/en/|archivedate=20 September 2015|df=}} 30. ^{{cite web|title=Onchocerciasis|url=http://www.who.int/mediacentre/factsheets/fs374/en/|publisher=World Health Organization|accessdate=3 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151007021424/http://www.who.int/mediacentre/factsheets/fs374/en/|archivedate=7 October 2015|df=}} 31. ^{{cite journal|last1=Sauerbrey|first1=M|title=The Onchocerciasis Elimination Program for the Americas (OEPA).|journal=Annals of Tropical Medicine and Parasitology|date=September 2008|volume=102 Suppl 1|pages=25–9|pmid=18718151|doi=10.1179/136485908x337454}} 32. ^{{Cite web|url=https://www.riverblindnessvaccinetova.org/|title=2020 vision of a vaccine against river blindness|last=|first=|date=|website=riverblindnessvaccinetova.org|archive-url=|archive-date=|dead-url=|access-date=}} 33. ^{{Cite journal|title=The Onchocerciasis Vaccine for Africa—TOVA—Initiative|last=Peter J. Hotez, Maria Elena Bottazzi, Bin Zhan, Benjamin L. Makepeace, Thomas R. Klei, David Abraham, David W. Taylor, and Sara Lustigman, Roger K Prichard|date=January 2015|pmc=4310604|pmid=25634641|doi=10.1371/journal.pntd.0003422|volume=9|issue=1|journal=PLoS Negl Trop Dis|page=e0003422}} 34. ^1 2 3 4 {{cite journal |title=Ivermectin and River Blindness |vauthors=Rea PA, Zhang V, Baras YS |journal=American Scientist |volume=98 |issue=4 |pages=294–303 |year=2010 |url=http://www.americanscientist.org/issues/feature/2010/4/ivermectin-and-river-blindness |deadurl=no |archiveurl=https://web.archive.org/web/20100705115143/http://www.americanscientist.org/issues/feature/2010/4/ivermectin-and-river-blindness |archivedate=2010-07-05 |df= }} 35. ^{{cite web |url=https://www.cdc.gov/parasites/onchocerciasis/treatment.html |title=Archived copy |accessdate=2017-05-15 |deadurl=no |archiveurl=https://web.archive.org/web/20170524051749/https://www.cdc.gov/parasites/onchocerciasis/treatment.html |archivedate=2017-05-24 |df= }} 36. ^{{cite book |author1=Trattler, Bill |author2=Gladwin, Mark |title=Clinical Microbiology Made Ridiculously Simple |publisher=MedMaster |location=Miami |year=2007 |pages= |isbn=978-0-940780-81-1 |oclc=156907378 }} 37. ^{{cite book |vauthors=Taylor MJ, Bandi C, Hoerauf A |title=Wolbachia bacterial endosymbionts of filarial nematodes |journal=Advances in Parasitology |volume=60 |issue= |pages=245–84 |year=2005 |pmid=16230105 |doi=10.1016/S0065-308X(05)60004-8 |url=http://linkinghub.elsevier.com/retrieve/pii/S0065-308X(05)60004-8|isbn=9780120317608 }} 38. ^1 {{cite journal |title=Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis |author=Hoerauf A |journal=Current Opinion in Infectious Diseases |year=2008 |volume=21 |issue=6 |pages=673–81 |pmid=18978537 |doi=10.1097/QCO.0b013e328315cde7}} 39. ^{{cite journal |vauthors=Yates DM, Wolstenholme AJ |title=An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis |journal=International Journal for Parasitology |volume=34 |issue=9 |date=August 2004 |pages=1075–81 |doi=10.1016/j.ijpara.2004.04.010 |pmid=15313134}} 40. ^{{cite journal |author=Harder A |title=Chemotherapeutic approaches to nematodes: current knowledge and outlook |journal=Parasitology Research |volume=88 |issue=3 |pages=272–7 |doi=10.1007/s00436-001-0535-x |pmid=11954915 |year=2002 }} 41. ^{{cite journal |journal=Parasitology |year=2005 |volume=131 |issue=Suppl:S85–95 |title=Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics |vauthors=Wolstenholme AJ, Rogers AT |pmid=16569295 |pages=S85–95 |doi=10.1017/S0031182005008218}} 42. ^{{cite journal |vauthors=Ejere HO, Schwartz E, Wormald R, Evans JR |title= Ivermectin for onchocercal eye disease (river blindness) |journal=Cochrane Database Syst Rev |volume=8 |issue= 8 |pages= CD002219 |date=2012 |pmid= 22895928|doi= 10.1002/14651858.CD002219.pub2 |pmc=4425412}} 43. ^1 {{cite web |title=Moxidectin tablets, for oral use |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf |website=www.accessdata.fda.gov |accessdate=7 January 2019}} 44. ^{{cite journal|last=Fenwick|first=A|title=The global burden of neglected tropical diseases.|journal=Public Health|date=Mar 2012|volume=126|issue=3|pages=233–6|pmid=22325616|doi=10.1016/j.puhe.2011.11.015}} 45. ^{{cite web |url=http://www.sightsavers.org/What%20We%20Do/Eye%20Conditions/River%20Blindness/World1622.html |title=What is river blindness? |accessdate=2008-01-28 |publisher=Sightsavers International |archiveurl = https://web.archive.org/web/20071215140210/http://www.sightsavers.org/What+We+Do/Eye+Conditions/River+Blindness/World1622.html |archivedate = 2007-12-15}} 46. ^{{cite web |publisher=World Health Organization |title=Status of onchocerciasis in APOC countries |url=http://www.who.int/apoc/onchocerciasis/status/en/index.html |year=2008 |accessdate=2010-04-26 |deadurl=no |archiveurl=https://web.archive.org/web/20100705125037/http://www.who.int/apoc/onchocerciasis/status/en/index.html |archivedate=2010-07-05 |df= }} 47. ^1 {{cite web |url=http://www.stanford.edu/class/humbio103/ParaSites2006/Onchocerciasis/Epidemiology.html |title=Epidemiology |publisher=Stanford University |year=2006 |deadurl=no |archiveurl=https://web.archive.org/web/20070922121742/http://www.stanford.edu/class/humbio103/ParaSites2006/Onchocerciasis/Epidemiology.html |archivedate=2007-09-22 |df= }} 48. ^{{Cite web|url=http://pharmacologyonline.silae.it/files/newsletter/2011/vol1/095.gaware.pdf|title=ONCHOCERCIASIS: AN OVERVIEW|last=Vinayak M Gaware, Kiran B Dhamak1, Kiran B Kotade, Ramdas T Dolas, Sachin B Somwanshi, Vikrant K Nikam, Atul N Khadse|date=|website=PhOL - PharmacologyOnLine|archive-url=|archive-date=|dead-url=|access-date=}} 49. ^{{cite journal |author1=Peña Flores G. |author2=Richards F. | year = 2010 | title = Lack of Onchocerca volvulus transmission in the northern focus in Chiapas | url = | journal = Am. J. Trop. Med. Hyg. | volume = 83 | issue = 1| pages = 15–20 | doi=10.4269/ajtmh.2010.09-0626|pmid=20595471 |pmc=2912569 |display-authors=etal}} 50. ^{{cite journal |author1=Peña Flores G. |author2=Richards F. |author3=Domínguez A. | year = 2010 | title = Interruption of transmission of Onchocerca volvulus in the Oaxaca focus | url = | journal = Am. J. Trop. Med. Hyg. | volume = 83 | issue = 1| pages = 21–27 | doi=10.4269/ajtmh.2010.09-0544|pmc=2912570 | pmid=20595472}} 51. ^{{cite journal|last1=Zimmerman|first1=PA|last2=Katholi|first2=CR|last3=Wooten|first3=MC|last4=Lang-Unnasch|first4=N|last5=Unnasch|first5=TR|title=Recent evolutionary history of American Onchocerca volvulus, based on analysis of a tandemly repeated DNA sequence family.|journal=Molecular Biology and Evolution|date=May 1994|volume=11|issue=3|pages=384–92|pmid=7516998|doi=10.1093/oxfordjournals.molbev.a040114}} 52. ^{{cite journal|last1=O’Neill|first1=John|title=O'Neill J. On the presence of a filaria in craw-craw|journal=The Lancet|date=1875|pages=265–266|url=https://web.stanford.edu/class/humbio103/ParaSites2006/Onchocerciasis/filaria_original_description.pdf|doi=10.1016/s0140-6736(02)30941-3|volume=105|issue=2686|deadurl=no|archiveurl=https://web.archive.org/web/20160202041235/https://web.stanford.edu/class/humbio103/ParaSites2006/Onchocerciasis/filaria_original_description.pdf|archivedate=2016-02-02|df=}} 53. ^{{cite web|title=A Short History of Onchocerciasis|url=https://www.scribd.com/doc/268204602/A-Short-History-of-Onchocerciasis|accessdate=18 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20160304071504/https://www.scribd.com/doc/268204602/A-Short-History-of-Onchocerciasis|archivedate=4 March 2016|df=}} 54. ^{{cite journal|last1=Robles|first1=Roberto|title=Enfermedad nueva en Guatemala|journal=La Juventud Médica|date=1917}} 55. ^{{cite book|last1=Strong|first1=Richard|title=Stitt's Diagnosis, prevention and treatment of tropical diseases|date=1942|publisher=The Blakiston}} 56. ^{{cite book|last1=Manson-Bahr|first1=Philip H|title=Tropical diseases; a manual of the diseases of warm climates [Internet]|date=1943|publisher=Williams & Wilkins Co|edition=11th}} 57. ^{{cite journal|last1=Blacklock|first1=DB|title=THE INSECT TRANSMISSION OF ONCHOCERCA VOLVULUS (LEUCKART, 1893): THE CAUSE OF WORM NODULES IN MAN IN AFRICA.|journal=British Medical Journal|date=22 January 1927|volume=1|issue=3446|pages=129–33|pmid=20772951|doi=10.1136/bmj.1.3446.129|pmc=2453973}} 58. ^{{cite journal|last1=Kluxen|first1=G|last2=Hoerauf|first2=A|title=The significance of some observations on African ocular onchocerciasis described by Jean Hissette (1888-1965)|journal=Bull Soc Belge Ophtalmol|date=2008|volume=307|pages=53–8}} 59. ^{{cite book|last1=Hisette|first1=Jean|title=Mémoire sur l'Onchocerca volvulus Leuckart et ses manifestations oculaires au Congo belge|date=1932|pages=433–529}} 60. ^{{cite journal|last1=Ridley|first1=Harold|title=OCULAR ONCHOCERCIASIS Including an Investigation in the Gold Coast|journal=Br J Ophthalmol|date=1945|volume=29|issue=Suppl|pages=3–58|doi=10.1136/bjo.29.suppl.3|pmid=18170175|pmc=513929}} 61. ^{{cite web|last1=Kluxen|first1=G|title=Harvard African Expedition [Internet]|url=http://collections.countway.harvard.edu/onview/items/show/6157|accessdate=18 October 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151222160904/http://collections.countway.harvard.edu/onview/items/show/6157|archivedate=22 December 2015|df=}} 62. ^{{cite journal |journal=Trop Med Int Health |date=May 2008 |volume=13 |issue=5 |pages=689–96 |title=Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis|vauthors=Thylefors B, Alleman MM, Twum-Danso NA |pmid=18419585 |doi=10.1111/j.1365-3156.2008.02049.x }} 63. ^{{citation |url=https://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/advanced-medicineprize2015.pdf |title=Avermectin and Artemisinin - Revolutionary Therapies against Parasitic Diseases |author1=Jan Andersson |author2=Hans Forssberg |author3=Juleen R. Zierath |publisher=The Nobel Assembly at Karolinska Institutet |date=5 October 2015 |accessdate=5 October 2015 |deadurl=no |archiveurl=https://web.archive.org/web/20151005235033/http://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/advanced-medicineprize2015.pdf |archivedate=5 October 2015 |df= }} 64. ^Kinship Powerful in River Blindness Fight. Carter Center Update, The Carter Center, Atlanta, Georgia. Summer, 2016. pp. 4-5. 65. ^{{cite journal |vauthors=Allen JE, Adjei O, Bain O, Hoerauf A, Hoffmann WH, Makepeace BL, Schulz-Key H, Tanya VN, Trees AJ, Wanji S, Taylor DW |title=Of Mice, Cattle, and Humans: The Immunology and Treatment of River Blindness |journal=PLoS Negl Trop Dis |volume=2 |issue=4 |date=April 2008 |pmid=18446236 |pmc=2323618 |doi=10.1371/journal.pntd.0000217 |pages=e217 |editor1-last=Lustigman |editor1-first=Sara}} {{open access}} 66. ^{{cite news |url=http://news.bbc.co.uk/2/hi/health/6753003.stm |publisher=BBC News |title=River blindness resistance fears |accessdate=2007-06-15 |date=2007-06-14 |deadurl=no |archiveurl=https://web.archive.org/web/20070808233457/http://news.bbc.co.uk/2/hi/health/6753003.stm |archivedate=2007-08-08 |df= }} 67. ^{{cite journal |vauthors=Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK |title=Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study |journal=Lancet |volume=369 |issue=9578 |pages=2021–9 |date=June 2007 |pmid=17574093|doi=10.1016/S0140-6736(07)60942-8 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(07)60942-8}} 68. ^{{cite journal |journal=Lancet |title=Fighting river blindness and other ills |volume=374 |issue=9684|page=91 |date=11 July 2009 |pmid=19595328 |doi=10.1016/S0140-6736(09)61262-9 |author=[No author listed]}} (editorial) 69. ^{{cite journal |vauthors=Abegunde AT, Ahuja RM, Okafor NJ |title= Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis |journal=Cochrane Database Syst Rev |volume=1 |issue= 1 |pages= CD011146 |date=2016 |pmid= 26771164 |doi= 10.1002/14651858.CD011146.pub2|pmc=5029467 }} External links{{portal bar|Medicine}}{{Medical condition classification and resources| DiseasesDB = 9218 | ICD10 = {{ICD10|B|73||b|65}} | ICD9 = {{ICD9|125.3}} | ICDO = | OMIM = | MedlinePlus = | eMedicineSubj = med | eMedicineTopic = 1667 | eMedicine_mult = {{eMedicine2|oph|709}} | MeshID = D009855 }}{{Wiktionary}}
8 : Spirurida|Tropical diseases|Helminthiases|Neglected diseases|Infectious diseases with eradication efforts|Parasitic infestations, stings, and bites of the skin|RTT|RTTID |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。